Slides
Page 1
Creating a World Class Platform © 2026 AtriCure, Inc. All rights reserved. JP Morgan Healthcare Conference Presentation January 2026
Page 2
© 2026 AtriCure, Inc. All rights reserved. 2 Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure’s expected market opportunity, guidance, future business, financial performance, financial condition, and results of operations, and often contain words such as “intends,” “estimates,” “anticipates,” “hopes,” “projects,” “plans,” “expects,” “drives,” “seek,” “believes,” "see," “focus,” “should,” “will,” “would,” “can,” “opportunity,” “target,” “outlook,” “guidance,” and similar expressions and the negative versions thereof. Such statements are based only upon current expectations of AtriCure. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates, projections or expectations reflected or contained in the forward-looking statements as a result of various risk factors. These risks and uncertainties include, but are not limited to, the following: our estimate of the market for our products; the rate and degree of market acceptance of our products; negative clinical data; competition from existing and new products and procedures, including the development of drugs or catheter-based technologies; our reliance on independent distributors to sell our products; inventory related charges; the timing of and ability to obtain and maintain regulatory clearances and approvals for our products; impacts of rising healthcare costs; our ability to comply with extensive FDA regulations; the timing of and ability to obtain third party payor reimbursement of procedures utilizing our products; unfavorable publicity; the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make; disruptions to our manufacturing operations; the impact of tariffs or other restrictive trade measures; our failure to properly manage growth; disruptions of critical information systems or material breaches in the security of our systems; our ability to manage our intellectual property rights to provide meaningful protection; fluctuation of quarterly financial results; fluctuations in foreign currency exchange rates; reliance on third party manufacturers and suppliers; regional, national or global political, economic, business, competitive, market and regulatory conditions; and litigation, administrative or other proceedings. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 14, 2025 and our quarterly reports on Form 10-Q. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change unless required by law. To supplement AtriCure’s consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures as supplemental financial metrics in this presentation. Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, and non-recurring charges that are not reflective of the operational results of the Company’s core business and may affect comparability of results period-over-period. Non-recurring charges include acquisition costs, acquired in-process research and development (IPR&D) and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. Adjusted EBITDA margin is Adjusted EBITDA divided by revenue. Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, acquired IPR&D and related milestone payments arising from asset acquisitions, legal settlement costs, impairment of intangible assets and debt extinguishment. The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non- GAAP financial measures to the comparable GAAP financials measures, and not to rely on any single financial measure to evaluate our business.
Page 3
Large and Growing Markets Addressing underserved and growing patient populations, representing over $10B opportunity Strong Portfolio Existing products and solutions and continuous innovation driving consistent, profitable growth Our Bright Future Creating and delivering standards of care to improve the lives of patients We are passionately focused on healing the lives of those affected by Afib and pain after surgery Our Vision © 2026 AtriCure, Inc. All rights reserved. Global Leader with Local Roots Leader in our markets, reaching 58 countries, dedicated to our roots in the United States 3
Page 4
Afib: A Serious Problem © 2026 AtriCure, Inc. All rights reserved. 4 5x Higher Risk of Stroke 46% Greater Risk of Mortality >5x Higher Risk of Heart Failure >3x Higher Risk of Dementia Afib affects more than 59 million people worldwide. It is estimated that 45% have suffered more than a year from Afib. 4
Page 5
© 2026 AtriCure, Inc. All rights reserved. 5 30%-50% of patients report persistent pain lasting months to years post-surgery 1 in 7 thoracotomy patients develop an opioid addiction 1 in 11 minimally invasive lung surgery patients develop an opioid addiction Pain after surgery slows recovery. A Persistent Pain Problem Pain after surgery increases healthcare costs. Pain after surgery reduces quality of life.
Page 6
6 Evolution of Our Global Market Opportunity © 2026 AtriCure, Inc. All rights reserved. Market opportunity and penetration estimates based on internal estimates and research, as well as from publicly available information. Leading with Innovation, Clinical Science and Awareness to establish and grow our markets $5B+ Current Markets $1B 2010 $10B+ Global Market Opportunity by 2030
Page 7
Establishing AtriCure as the Standard of Care Estimated Total Market Opportunity Our Vision for Standard of Care Key Drivers Innovation Clinical Science Awareness Globally, all Cardiac Surgery patients benefit from ablation + AtriClip to reduce Afib and strokes. ~$7B+ Nearly 2 million patients annually EnCompass Clamp + AtriClip Dedicated Field Team Guidelines & Reimbursement Robust Education, Awareness LeAAPS Clinical Trial BoxX-NoAF Clinical Trial Cardiac Surgery Increase treatment of LS Persistent Afib patients with minimally invasive ablation + AtriClip. ~$3B+ Over 200,000 patients annually EPi-Sense System + AtriClip EP Focused Field Team Guidelines & Reimbursement Robust Education, Awareness CONVERGE Data CEASE AF and DEEP Studies PFA Platform Hybrid Therapies Cryo Nerve Block reduces pain, minimizes narcotic use, and improves recovery time in surgical procedures. ~$2B Nearly 1 million patients annually cryoSPHERE+, MAX, cryoXT Cryo Platform Dedicated Field Team Patient Awareness FROST Trial Economic Studies REDUCE Registry Pain Management 7© 2026 AtriCure, Inc. All rights reserved. Market opportunity based on internal estimates and research, as well as from publicly available information.
Page 8
Establishing AtriCure as the Standard of Care Estimated Total Market Opportunity Our Vision for Standard of Care Key Drivers Innovation Clinical Science Awareness Globally, all Cardiac Surgery patients benefit from ablation + AtriClip to reduce Afib and strokes. ~$7B+ Nearly 2 million patients annually -- 300k United States -- EnCompass Clamp + AtriClip Dedicated Field Team Guidelines & Reimbursement Robust Education, Awareness LeAAPS Clinical Trial BoxX-NoAF Clinical Trial Cardiac Surgery 8© 2026 AtriCure, Inc. All rights reserved. Market opportunity based on internal estimates and research, as well as from publicly available information. ISOLATOR® SYNERGY ENCOMPASS ® CLAMP ATRICLIP FLEX•MiniTM DEVICE
Page 9
Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice © 2026 AtriCure, Inc. All rights reserved. 9 Lasts beyond 7 days and as long as 1 year Lasts longer than 1 year without stopping Sources included in Appendix
Page 10
© 2026 AtriCure, Inc. All rights reserved. 10 Lasts longer than 1 year without stopping Treatment of Afib and LAAM Improving Access through Reimbursement 2021 2022 2023 2024 Hospital Reimbursement MS-DRG 233, 234 CABG + Surgical Ablation $8k-$14k for addition of ablation Physician Reimbursement CPT 33267, 33268, 33269 Epicardial LAA First time physician payment / RVU for surgical LAA Hospital Reimbursement MS-DRG 212 AVR + MVR + Surgical Ablation $24k for addition of ablation Hospital Reimbursement MS-DRG 317 Epicardial Ablation + Epicardial LAA $15k - $20k for combination Sources included in Appendix
Page 11
IDE Trial to evaluate the effectiveness of prophylactic LAA exclusion for prevention of ischemic stroke or systemic arterial embolism in cardiac surgery patients without pre-operative Afib diagnosis © 2026 AtriCure, Inc. All rights reserved. LeAAPS Overview Primary Endpoints Effectiveness First occurrence of ischemic stroke or systemic arterial embolism. Safety Incidence of safety events through 30-days to demonstrate no increase in risk with LAA exclusion during cardiac surgery. Study Design Summary Multi-center, prospective, randomized control (1:1) trial Number of Subjects and Sites Up to 6,500 subjects at up to 250 sites worldwide Study Duration Safety: 30-day follow-up Efficacy: Event-driven trial, with a minimum follow-up of 5 years post procedure Using AtriClip® LAA Exclusion System CLINICAL TRIAL Le ft Atrial Appendage Exclusion for P rophylactic S troke Reduction • Seminal clinical trial – one of the largest IDE trials in cardiac surgery • Study has global reach with sites in the United States, Canada, Europe and Asia • Over 500 surgeons across 133 sites participated in the trial • Timeline: Q2 2022: FDA approval of LeAAPS clinical trial protocol Q1 2023: First patient treated Q3 2025: Enrollment completed Patient follow-up ongoing Multiple secondary and other key endpoints will be evaluated Highlights 11
Page 12
12 BoxX-NoAF Overview IDE Trial to demonstrate that left atrial concomitant ablation and left atrial appendage exclusion during cardiac surgery are safe and effective to reduce post-operative Afib (POAF) and clinical Afib in patients without documented history of Afib but with risk factors of developing POAF and clinical Afib Using Isolator® Synergy EnCompass® Ablation System and AtriClip® LAA Exclusion System • POAF is the most common complication of cardiac surgery; POAF incidence can be greater than 50% • Patients with POAF tend to have worse acute and long-term clinical outcomes, including high risk of developing long- term clinical Afib • Administrative claims analysis has demonstrated that POAF is associated with higher healthcare cost burden • Currently, there is no FDA approved therapy to prevent POAF in cardiac surgery patients • Trial design and endpoints based on published data covering thousands of patients, including prospective RCTs • First patient treated (Q4 2025) Highlights & Study Rationale Endpoints Primary Effectiveness Occurrence of clinically relevant post- operative Afib (POAF) 30 days post index cardiac surgical procedure Secondary Effectiveness Time to first occurrence of clinical Afib from 30 days after index cardiac surgical procedure through 3-years Safety Incidence of specified safety events through 30 days Study Design Summary Multi-center, prospective, randomized control (1:1) trial Number of Subjects and Sites Up to 960 subjects at 75 sites worldwide Study Duration Safety: 30-day follow-up Efficacy: Event-driven trial, with endpoints at 30 days and 3-years post procedure Box Lesion Creation with LAA EXclusion to Prevent New-onset Atrial Fibrillation in Cardiac Surgery Patients © 2026 AtriCure, Inc. All rights reserved.
Page 13
Establishing AtriCure as the Standard of Care Estimated Total Market Opportunity Our Vision for Standard of Care Key Drivers Innovation Clinical Science Awareness Cryo Nerve Block reduces pain, minimizes narcotic use, and improves recovery time in surgical procedures. ~$2B Nearly 1 million patients annually -- 580k United States -- cryoSPHERE+, MAX, cryoXT Cryo Platform Dedicated Field Team Patient Awareness FROST Trial Economic Studies REDUCE Registry Pain Management 13© 2026 AtriCure, Inc. All rights reserved. Market opportunity based on internal estimates and research, as well as from publicly available information. 60 Seconds to Manage Post-Operative Pain with cryoSPHERE MAX cryoXT® DEVICE for Amputations
Page 14
Major Amputation Lower Extremity Amputation Initial Target Vascular PVD Infection Diabetic © 2026 AtriCure, Inc. All rights reserved. CRYO2 510(k) clearance for pain management First FROST patient enrolled cryoSPHERE 510(k) clearance and launch FDA clearance for Adolescent label FROST trial publication CNB used for sternotomy procedures cryoSPHERE+ and MAX 510(k) clearance and launch cryoXT for amputations 510(k) clearance and launch 2015 2016 2019 2020 2021 2023 2024 2025 Pain Management A Decade of Progress Post-Operative pain was a problem we identified and leveraged our history of addressing unmet clinical needs + ablation expertise to cultivate new markets. Cryo Nerve Block for Amputations is the next opportunity. ~180k amputations per year in United States Diabetes & dysvascular (PVD) disease = 70-85% of amputations in BKA patients Market drivers include prevalence of diabetes and lower limb disease Cryo Nerve Block is a differentiated solution that provides long-term durability with reproducible results, reducing residual limb pain and may prevent phantom limb pain. 180k ~100k+ 14 150k
Page 15
$1B Annual Revenue 2030 20%+ Adjusted EBITDA Margin 75%+ FCF conversion Robust Operating Cash Flow for a Sustainable Future ~$750M+ Annual Revenue 2028 ~14% Adjusted EBITDA Margin Steady to Improving Margins and Cash Flow Supporting continued reinvestment © 2026 AtriCure, Inc. All rights reserved. 15 $535M 2025 Annual Revenue 14.9% 2025 Revenue Growth 10.8% 2025 Adjusted EBITDA Margin Guidance Future Built from Innovation and Operational Excellence End of Decade Goals* Next 3 Years* 2025* 2025 Performance and 2026 Outlook outpacing our long-term goals *2025 Revenue is preliminary and unaudited. 2025 Adjusted EBITDA margin guidance calculated at midpoint of range. 2028 and 2030 Targets are aspirational and do not constitute formal guidance. Free Cash Flow (FCF) conversion rate is FCF divided by Adjusted EBITDA.
Page 16
Milestones Supporting Our Vision 16© 2026 AtriCure, Inc. All rights reserved. • AtriClip Pro-Mini • cryoXT Probe • LeAAPS fully enrolled • Initiate BoxX-NoAF • First In-Human with PFA • AtriClip FLEX-Mini • cryoSPHERE+ / MAX • Int’l product expansion • EnCompass clamp 2024–2025 • cryoXT launch • BoxX-NoAF enrollment • Cryo platform built • Initiate EnCompass PFA IDE • Next AtriClip innovation • LeAAPS follow-up • HEAL IST data 2026–2027 • Next gen EnCompass • BoxX-NoAF PMA – POAF indication • LeAAPS data and PMA – stroke indication • BoxX-NoAF PMA – Clinical Afib indication • PFA platform device PMA • $1B in revenue with 20%+ Adj EBITDA margin at end of decade 2028 and beyond
Page 17
Key New Product Launches 2025 Highlights and Accomplishments 15% Enrollment Completed Annual Revenue Growth* Top Workplace Honors Cincinnati, Minneapolis, Netherlands, Australia, United Kingdom +86% Increase in Positive Adjusted EBITDA** Improving profitability while driving growth *2025 Revenue is preliminary and unaudited. ** 2025 Positive Adjusted EBITDA based on mid-point of 2025 guidance range of $57 million to $59 million. © 2026 AtriCure, Inc. All rights reserved. ATRICLIP FLEX•Mini ATRICLIP PRO•Mini Pain Management: LAAM: International Expansion • AtriClip devices approved in Japan • cryoSPHERE MAX launched in EU HQ Facility expansion 17 First patient treated First in Human! Dual energy platform enabling EnCompass clamp PFA First year cash generation cryoSPHERE MAX cryoXT
Page 18
Financial Results and 2026 Outlook 18 Worldwide Revenue 2026 Guidance Worldwide Revenue $600 million to $610 million Approximately 12-14% YoY growth Adjusted EBITDA $80 million to $82 million Positive Net Income for full year 2026 Continued Cash Generation for full year 2026 +20% +21% +17% Adjusted EBITDA ($ Millions) * 2025 Worldwide Revenue is preliminary and unaudited. 2025 Adjusted EBITDA based on midpoint of guidance range. ** 2026 Worldwide Revenue and 2026 Adjusted EBITDA based on midpoint of guidance range. Significant Investment in Growth Catalysts while Expanding Operating Leverage © 2026 AtriCure, Inc. All rights reserved. +15% +13%
Page 19
Distinct Opportunity for Value Creation As We Execute Our Vision #1 Leader in each market. Unrivaled commitment to develop and support our partners and patients. Driving profitable growth. Bright outlook for revenue growth coupled with operating leverage. Robust, organic R&D pipeline. Broad Innovation and Clinical Science initiatives across platforms. Vastly underpenetrated markets. Ability to grow within existing markets as we cultivate new opportunities. © 2026 AtriCure, Inc. All rights reserved. 19
Page 20
Thank You! © 2026 AtriCure, Inc. All rights reserved.
Page 21
Key Products © 2026 AtriCure, Inc. All rights reserved. 21 EPI-SENSE ® DEVICE ATRICLIP PRO・V® DEVICE ATRICLIP ® FLEX・V ® DEVICE ISOLATOR® SYNERGY CLAMP cryoSPHERE ® CRYOABLATION PROBE ISOLATOR® SYNERGY ENCOMPASS ® CLAMP ATRICLIP FLEX•MiniTM DEVICE cryoSPHERE ® MAX PROBE cryoXT® DEVICE
Page 22
2010+ 22 Innovation and Clinical Milestones © 2026 AtriCure, Inc. All rights reserved. • Synergy system FDA approved for treatment of Afib concomitant to open heart procedures • AtriClip ® devices • CONVERGE Trial begins • EPi-Sense® system acquired • AtriClip PRO-V® • AtriClip Flex-V® • Concomitant Ablation now Class 1A Guideline • cryoSPHERE ® probe for Pain Management • EPi-Sense approved by FDA for treatment of long-standing persistent Afib • EnCompass ® clamp • LeAAPS Trial studying prophylactic LAA exclusion in non-Afib patients begins • EPi-Sense ST device • Surgical LAA Exclusion now Class 1A Guideline • Reimbursement improves • cryoSPHERE+ and MAX probes • AtriClip FLEX-Mini device • AtriClip PRO-Mini device • cryoXT probe for amputations • BoxX-NoAF Trial studying prophylactic ablation of non-Afib patients begins 2015+ 2020+
Page 23
References © 2026 AtriCure, Inc. All rights reserved. Page Metric Reference 4 59 million people with Afib Worldwide Linz, D., Gawalko, M., Betz, K., Hendriks, J. M., Lip, G. Y., Vinter, N., Guo, Y. & Johnsen, S. (2024). Atrial fibrillation: epidemiology, screening and digital health. The Lancet Regional Health–Europe, Volume 37, 100786, February 2024 4 45% with Afib greater than 1 year Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014 Jun 16;6:213-20. doi: 10.2147/CLEP.S47385. PMID: 24966695; PMCID: PMC4064952 4 5x higher risk of stroke; Odutayo, A. et al. (2016). Atrial fibrillation and risks of cardiovascular disease, renal disease, and deaths systematic revi ew and meta analysis. BMJ 2016; 354:i4482 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N-9N. doi: 10.1016/s0002-9149(98)00583- 9. PMID: 9809895 4 46% greater risk of mortality Boriani G, Proietti M (2017) Atrial fibrillation prevention: an appraisal of current evidence. Heart (0):1– 6 Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6 213- 220 4 >5x higher risk of heart failure Boriani G, Proietti M (2017) Atrial fibrillation prevention: an appraisal of current evidence. Heart (0):1– 6 4 >3x higher risk of dementia Bunch TJ et al. Arrhythmia & Electrophysiology Review 2019;8(1):8–12 Zhang W, Liang J, Li C, Gao D, Ma Q, Pan Y, Wang Y, Xie W, Zheng F. Age at Diagnosis of Atrial Fibrillation and Incident Dementi a. JAMA Netw Open. 2023 Nov 1;6(11):e2342744. doi: 10.1001/jamanetworkopen.2023.42744. PMID: 37938842; PMCID: PMC10632957 5 30-50% patients report persistent pain lasting months after surgery Bayman, E.O., Parekh, K. R. Keech, J., Selte, A., & Brennan, T.J. (2017). A prospective study of chronic pain after thoracic surgery. Anesthesiology: The Journal of the American Society of Anesthesiologists, 126(5), 938- 951. Niraj, G., Kelkar A., Kaushik, V., Tang, Y., Fleet, D., Tait, F., … & Rathinam, S. (2017). Audit of postoperative pain management after open thoracotomy and the incidence of chronic posthoracotomy pain in more than 500 patients at a tertiary center. Journal of clinical anesthesia, 36, 174- 177. Maguire, M. F., Latter, J. A. Mahajan, R., Beggs, F.D., & Duffy, J. P. (2006). A study exploring the role of intercostal nerv e damage in chronic pain after thoracic surgery. European journal of cardio – thoracic surgery, 29 (6), 873-879. 5 1 in 7 thoracotomy patients develop opioid addiction 1 in 11 minimally invasive lung surgery patients develop an opioid addiction The Society of Thoracic Surgeons, Current News Release (1/30/2018): 1 in 7 Lung Surgery Patients at Risk for Opioid Dependenc e 12 POAF is the most common complication of cardiac surgery; POAF incidence can be greater than 50% Gaudino et al. Lancet 2021. DOI: 10.1016/S0140-6736(21)02490-9 Predictors of Atrial Fibrillation After Coronary Artery Surgery. Circulation. 1996;94:39n. 1996;94:390– 397 Raiten et al, Atrial Fibrillation After Cardiac Surgery: Clinical update on the Mechanisms and Prophylactic Strategies, Journal of Cardiovascular and Thoracic Anesthesia, Vo 26. No 3, (June) 2015, pp 808- 816. Lomivorotov et al, New-onset Atrial Fibrillation After Cardiac Surgery: Pathophysiology, Prophylaxis, and Treatment, Journal of Cardiovascular and Thoracic Anesthesia, Vo 30. No 1, (February) 2016, pp 208- 216. 12 Patients with POAF tend to have worse acute and long-term clinical outcomes, including high risk of developing long-term clinical Afib Gaudino et al. Lancet 2021. DOI: 10.1016/S0140-6736(21)02490-9 Caldonazo T, et al.. Atrial fibrillation after cardiac surgery: a systematic review and meta- analysis. J Thorac Cardiovasc Surg 2023;165:94–103.e24. 10.1016/j.jtcvs.2021.03.077 Eikelboom R, et al. Postoperative atrial fibrillation after cardiac surgery: a systematic review and meta- analysis. Ann Thorac Surg 2021;111:544–554. Goyal P, et al.. Post-operative atrial fibrillation and risk of heart failure hospitalization. Eur Heart J 2022;43:2971–2980. 10.1093/eurheartj/ehac285 12 Administrative claims analysis has demonstrated that POAF is associated with higher healthcare cost burden Almassi GH, et al.. New-onset postoperative atrial fibrillation impact on 5-year clinical outcomes and costs. J Thorac Cardiovasc Surg 2021;161:1803–1810.e3. 10.1016/j.jtcvs.2019.10.150 Rosamond W et al.. Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Comm ittee and Stroke Statistics Subcommittee. Circulation 2007;115:e69–171. 10.1161/CIRCULATIONAHA.106.179918 14 Amputation market trends Dillingham TR, Pezzin LE, MacKenzie EJ. Limb amputation and limb deficiency: epidemiology and recent trends in the United States . South Med J. 2002 Aug;95(8):875-83. doi: 10.1097/00007611-200208000-00018. PMID: 12190225. Varma P, Stineman MG, Dillingham TR. Epidemiology of limb loss. Phys Med Rehabil Clin N Am. 2014 Feb;25(1):1-8. doi: 10.1016/j.pmr.2013.09.001. PMID: 24287235; PMCID: PMC4533906. 23
Page 24
© 2026 AtriCure, Inc. All rights reserved. 24 Sources Tables January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland Jr, J. C., ... & Yancy, C. W. (2019). 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation, 140(2), e125-e151. Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., ... & Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1-e156. Wyler von Ballmoos, M. C. W., Hui, D. S., Mehaffey, J. H., Malaisrie, S. C., Vardas, P. N., Gillinov, A. M., ... & Badhwar, V. (2024). The Society of Thoracic Surgeons 2023 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation. The Annals of Thoracic Surgery. Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J., ... & Kotecha, D. (2024). 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal, ehae176. Sources: Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice Sources: Treatment of Afib and LAAM Improving Access through Reimbursement In 2021, CMS moved CABG plus ablation cases to MS-DRGs 223/234 from MS-DRGs 235/236. In 2022, CMS physician payment rates included new surgical LAA codes (CPT 33267, 33268, 33269). In 2023, CMS created MS-DRG 212 which moves cases with an AVR plus and MVR plus an ablation from MS-DRGs 216-221 to MS-DRG 212. In 2024, CMS created MS-DRG 317 which moves cases with ablation plus LAAM from MS-DRG 228/229 to MS-DRG 317. Healthcare providers are solely responsible for the accuracy of codes selected for the services rendered and reported. AtriCure does not assume responsibility for coding decisions, nor recommend codes for specific cases. AtriCure also does not promote off-label use of its devices.
Page 25
Abbreviations © 2026 AtriCure, Inc. All rights reserved. 25 Key Abbreviations Afib or AF Atrial Fibrillation AVR Aortic Valve Repair / Replacement BKA Below the Knee Amputation CABG Coronary Artery Bybass Graft CNB Cryo Nerve Block CPT Current Procedural Terminology code EP Electrophysiologist FDA Food & Drug Administration IDE Investigational Device Exemption IST Inappropriate Sinus Tachycardia LAA Left Atrial Appendage LAAM LAA Management MS-DRG Medicare Severity Diagnosis Related Groups MVR Mitral Valve Repair/Replacement PFA Pulsed Field Ablation PMA Pre-Market Approval POAF Post-Op Afib RVU Relative Value Unit